Tag: Senolytics

The global market for anti-aging products was valued at $253 million in 2020 and is projected to reach $386 million by the end of 2027. This growth reflects intense public interest in discovering a single "wonder drug for anti-aging?". While a magical pill is still science fiction, modern pharmacology is exploring several promising compounds that target the biological processes of aging.

In July 2024, NPR reported on a clinical trial testing rapamycin, a generic drug known to extend lifespan in animals, for its potential anti-aging effects in humans. The 'NPR longevity drug' primarily refers to **rapamycin**, though NPR has covered other compounds, such as metformin and senolytics, underscoring the growing field of pharmacological interventions aimed at delaying age-related decline.

Despite decades of research, no single drug is currently approved by the FDA with proven anti-aging effects in humans. The scientific community, however, is actively investigating various compounds, exploring the question of what drug slows aging and its related diseases.